Evidence map›Paper›PMID 42179341›Full record

ArticleIntegrative cancer therapies

Triptolide enhances anti-cancer activities of irinotecan in human colon cancer HT-29 cells

Yi-Shih Ma, Fu-Shin Chueh, Yi-Ping Huang, Shu-Fen Peng, Chao-Lin Kuo, Jaw-Chyun Chen, Fei-Ting Hsu, Kuang-Chi Lai, Yu-Jung Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Shih MaI-Shou University, Kaohsiung, Taiwan.
Fu-Shin ChuehAsia University, Taichung, Taiwan.
Yi-Ping HuangChina Medical University, Taichung, Taiwan.
Shu-Fen PengChina Medical University, Taichung, Taiwan.
Chao-Lin KuoChina Medical University, Taichung, Taiwan.
Jaw-Chyun ChenDa-Yeh University, Changhua, Taiwan.
Fei-Ting HsuNational Central University, Taoyuan, Taiwan.
Kuang-Chi LaiChina Medical University, Taichung, Taiwan.ORCID 0000-0001-7580-1222
Yu-Jung LinChang Bing Show-Chwan Memorial Hospital, Changhua County, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irinotecan (IRI), a clinically used anticancer drug, is effective against various solid tumors, including colorectal cancer, but its use is limited by side effects. Triptolide (TP), an alkaloid from

Indexed as

CamptothecinColonic NeoplasmsDiterpenesPhenanthrenesAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell SurvivalDrug SynergismEpoxy CompoundsHT29 CellsHumansIrinotecanMaleMiceMice, Inbred BALB CCamptothecinDiterpenesEpoxy CompoundsIrinotecanPhenanthrenesProto-Oncogene Proteins c-bcl-2triptolideapoptosiscaspaseHT-29 colon cancer cellsirinotecantriptolidexenograft

Identifiers

PMID42179341
PMCPMC13201951

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.